Loomis Sayles & Co. L P Has $97.19 Million Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Loomis Sayles & Co. L P reduced its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,207,060 shares of the company's stock after selling 36,207 shares during the quarter. Loomis Sayles & Co. L P owned 2.31% of PROCEPT BioRobotics worth $97,192,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Raleigh Capital Management Inc. acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at about $32,000. Signaturefd LLC increased its stake in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after acquiring an additional 145 shares during the period. IFP Advisors Inc bought a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $58,000. Wilmington Savings Fund Society FSB bought a new stake in shares of PROCEPT BioRobotics in the 3rd quarter worth approximately $64,000. Finally, Arcadia Investment Management Corp MI acquired a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $64,000. 89.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PRCT has been the subject of several research reports. Truist Financial reaffirmed a "buy" rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Morgan Stanley dropped their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $94.29.

Insider Buying and Selling

In other news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock worth $368,322 in the last 90 days. Corporate insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock traded down $2.86 during trading hours on Monday, hitting $57.19. 397,652 shares of the stock were exchanged, compared to its average volume of 749,108. PROCEPT BioRobotics Co. has a 12 month low of $45.56 and a 12 month high of $103.81. The business's 50-day moving average is $65.34 and its two-hundred day moving average is $77.82. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The stock has a market capitalization of $3.14 billion, a P/E ratio of -29.14 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. Equities research analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).